Ischemic preconditioning is not additive to preservation with hypothermia or crystalloid cardioplegia in the globally ischemic rat heart

The aim of this study was to evaluate the additive protective efficiency of ischemic preconditioning when used in combination with conventional clinically relevant cardioprotective methods of hypothermia or hypothermic cardioplegia during sustained global ischemia.Isolated rat hearts were aorta-perfused with Krebs-Henseleit buffer and were divided into six groups (n = 10 each). Group I: Ischemia at 34°C for 60 min; Group PC+I: preconditioned (PC) ischemia at 34°C, 2 episodes of 5 min ischemia and 10 min reperfusion at 34°C followed by I; Group HI: hypothermic ischemia at 10°C for 60 min; Group PC+HI: preconditioned (PC) hypothermic ischemia, 2 episodes of 5 min ischemia and 10 min reperfusion at 34°C followed by HI; Group CPL+HI: single dose of 'Plegisol' cardioplegia followed by HI; Group PC+CPL+HI: preconditioned hypothermic cardioplegia, followed by CPL+HI. At the end of 60 min ischemia, all the hearts were reperfused at 34°C for 30 min when post-ischemic recovery in left ventricular contractile function and coronary vascular dynamics was computed and compared.There was a significant depression in the post-ischemic recovery of developed pressure (P_max), positive derivative of pressure (+dp/dt), negative derivative of pressure (-dp/dt) and heterometric autoregulation (HA) of contractile force in all the groups, with no major differences between the groups. Left ventricular end-diastolic pressure (LVEDP) was significantly elevated after I at 34°C. Preconditioning (PC+I) prevented the rise in the LVEDP and this was accompanied by a significant reduction in the release of purine metabolises in the coronary effluents, particularly adenosine, during the immediate reperfusion period. Hypothermia (HI) provided essentially the same level of metabolic and mechanical preservation as offered by PC+I. Combination of hypothermia with preconditioning (PC+HI) or cardioplegia (PC+CPL+HI), did not further enhance the preservation. Post-ischemic recovery in the regional contractile function (segment shortening, %SS) followed nearly identical pattern to global (P_max) recovery. Post-ischemic recovery in coronary flow (CF) was significantly reduced and coronary vascular resistance (CVR) was significantly increased in all the groups. Myogenic autoregulation (transient and sustained) was generally enhanced indicating increased vascular reactivity. Preconditioning did not alter the time-course of these changes.Preconditioned ischemia (34°C) preserved left ventricular diastolic functions and prevented the contracture development after sustained ischemia reperfusion at 34°C. This protective effect of preconditioning was possibly mediated by the reduction in the breakdown of purine metabolises. Hypothermia alone or in combination with crystalloid cardioplegia prevented the irreversibility of the ischemic injury but produced contractile and vascular stunning which was not improved by ischemic preconditioning. The results of this study indicate that preconditioning when combined with hypothermia or hypothermic cardioplegia offered no significant additional protection.     

Detection of early ischemic damage by analysis of mitochondrial function in skinned fibers

The skinned fibers technique was applied for studies of the effects of global acute ischemia (1 h at 37°C) and long time (15 h) hypothermic (4°C) preservation of isolated rat hearts under different conditions (immersion or low-flow perfusion) on mitochondrial function in the cells in vivo. Skinned fibers were obtained by using saponin for permeabilization of the sarcolemma in separated fiber bundles cut from left ventricle. The experimental protocol of the respiration rate determination included a cytochrome c test to check the intactness of the outer mitochondrial membrane. The apparent K_m for ADP and the effect of creatine on the mitochondrial activity were also evaluated in these permeabilized fibers, taken from different groups of hearts. The preservation of low-flow perfused hearts resulted only in a slight decrease of creatine (20 mM) stimulated respiration at 0.1 mM ADP. The fibers from ischemic hearts or from hearts preserved by immersion showed a decrease of the apparent K_m for ADP, and a complete loss of the stimulatory effect of creatine. In these fibers, we could observe that the outer mitochondrial membrane was damaged. In conclusion, the results of this study show that assessment of mitochondrial parameters sensitive to organelles swelling – intactness of outer membrane and functionally coupled creatine kinase reaction – are the most sensitive indicators of early hypoxic or ischemic damage to mitochondria. Their determination in biopsy samples could be used for evaluation of the efficiency of the cardiac protection in heart surgery. (Mol Cell Biochem 174: 79–85, 1997)     

心脏晶体停搏液和冷血停搏液不同灌注方法对心肌保护的评价

目的：评估二种心脏停搏液不同灌注方法对心肌保护作用。方法：30例双瓣患者随机分为冷晶体停搏液间断灌注组(n=10),冷血停搏液间断灌注组(n=10),冷血停搏液持续灌注组(n=10),观察血浆心肌肌钙蛋白T(CnT)、肌酸激酶(CK)、肌酸激酶同工酶(CK—MB)。结果：体外循环后冷晶体停搏液间断灌注组血浆心肌肌钙蛋白T和肌酸激酶、肌酶激酶同工酶较其他2组明显增高;冷血停搏液间断灌注组和冷血停搏液持续灌注组血浆心肌肌钙蛋白T、肌酸激酶、肌酸激酶同工酶无明显差异。结论：冷血停搏液的心肌保护优于冷晶体停搏液,冷血停搏液间断灌注与持续灌注没有明显差异。     

河豚毒素停搏液对缺血／再灌注心肌细胞钠超载的影响

目的：观察Na^＋通道阻滞剂河豚毒素（TTX）极化心脏停搏液对离体大鼠心肌细胞内游离Na^＋浓度（[Na^＋]i）的影响。方法：成年Wistar大鼠心脏,用酶解法分离成具有搏动性的单个心室肌细胞悬液,随机分成基础组、STH2组（缺血／再灌注损伤对照组）和TTX组（实验组）,STH2组和TTX组分别应用St．ThomasⅡ号停搏液和TTX停搏液处理,建立模拟缺血／再灌注损伤的停搏／复搏细胞模型,激光扫描共聚焦显微镜（LSCM）测定各组细胞不同时期的[Na^＋]。倒置显微镜观察细胞形态学变化。结果：TTX组和STH2组细胞复搏后[Na^＋];均明显高于基础组（P〈0．01）,但TTX组明显低于STH2组（P〈0．01）;在停搏期间,TTX组细胞[Na^＋]i上升速度和幅度明显低于STH2组;形态学观察,TTX组复搏后具有正常活力的杆形心肌细胞比例高于STH2组（P〈0．01）。结论：河豚毒素心脏停搏液较去极化心脏停搏液能减轻心肌细胞Na^＋超载和缺血／再灌注损伤。     

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest

The following protocol is of use to evaluate impaired cardiac function or myocardial stunning following moderate ischemic insults. The technique is useful for modeling ischemic injury associated with numerous clinically relevant phenomenon including cardiac surgery with cardioplegic arrest and cardiopulmonary bypass, off-pump CABG, transplant, angina, brief ischemia, etc. The protocol presents a general method to model hypothermic hyperkalemic cardioplegic arrest and reperfusion in rodent hearts focusing on measurement of myocardial contractile function. In brief, a mouse heart is perfused in langendorff mode, instrumented with an intraventricular balloon, and baseline cardiac functional parameters are recorded. Following stabilization, the heart is then subject to brief infusion of a cardioprotective hypothermic cardioplegia solution to initiate diastolic arrest. Cardioplegia is delivered intermittently over 2 hr. The heart is then reperfused and warmed to normothermic temperatures and recovery of myocardial function is monitored. Use of this protocol results in reliable depressed cardiac contractile function free from gross myocardial tissue damage in rodents.     

不同温度“钾维普”停搏对幼大鼠心功能的影响

目的：探讨未成熟缺血心脏“钾维普”停搏保护的适宜温度。方法：离体幼大鼠心脏Langendorff法灌流,分5组（n=6—8）。对照组：360C正常灌流170min;36℃（常温）组：正常灌流20rain,灌“钾维普”停搏液（KVe）3min停灌87min（常温停搏90rain）,恢复正常灌流（复灌）60min;32、28、24℃（低温）组：正常灌流15min,5min内分别降温至32、28、24℃,灌KVP3rain停灌87min（低温停搏90min）,复灌60min。实验过程实时监测心率（h／min）、心肌张力（g）、收缩力（g）、最大收缩速度（dr／dtmax）、最大舒张速度（-dT／dtmax）及冠脉流量（drop/min）反映心功能。结果：与对照组相比,各组KVP停搏50min后心脏张力均增高;与低温停搏相比,常温停搏的心脏不良挛缩迟缓、复灌后心脏张力、心率、收缩力、冠脉流量恢复好（P〈0．05）。结论：未成熟缺血心脏常温“钾维普”停搏保护效果优于低温停搏。     

含血停搏液镁离子浓度对未成熟心肌保护的影响

目的 采用幼兔离体心脏模型。模拟临床上可能出现的含血停搏液Ca^2 浓度变化,探讨适宜于未成熟心肌保护的Mg^2 浓度。方法 3-4周龄长耳白兔,依照含血停搏液不同Mg^2 浓度（0.6mmol/L,4.0mmol/L,8.0mmol/L,120mmol/L,16.0mmol/L）随机分为5组,建立Langendorff离体心脏灌注模型。采用Ca^2 浓度1.2-1.5mmol/L的含血停搏液,运用温血停搏液诱导停搏,冷血停搏液间断灌注,低温保护,终末温血停搏液控制性再灌注技术,观察以下指标：1、血流动力学指标;实验前后恢复率;心率,主动脉流量,冠脉流量,心排量,左室收缩压和左室舒张末压;2、心肌含水量;3、冠脉流出液乳酸盐含量;4、心肌肌酸激酶和乳酸脱氢酶漏出率;5、心肌细胞内Na^2 ,Ca^2 含量;6、心肌组织ATP含量;7、心肌组织SOD活性,MDA含量;8、心肌超微结构。结果 1、心率恢复率,主动脉流量恢复率及左室收缩压恢复率组间总体差异无显著性。而冠脉流量恢复率,心排量恢复率和左室舒张末压恢复率以Mg^2 浓度8.0mmol/L和12.0mmol/L为优,0.4mmol/L组最差。2、心肌含水量以Mg^2 浓度8.0mmol/L和12.0mmol/L为最低。3、冠脉流出液乳酸盐含量0.4mmol/L组,8.0mmol/L和12.0mmol/L组高于欺科2组。4、心肌乳本能部氢酶漏出率以8.0mmol/L组最低,而肌酸激酶漏出率以8.0mmol/L和12.0mmol/L组为最低。5、心肌细胞内Na^ 、Ca^2 含量;6、心肌组织ATP含量;7、心肌组织SOD活性,MDA含量;8、心肌超微结构。结果：1、心率恢复率,主动脉流量恢复率及左室收缩压恢复率组间总体差异无显著性。而冠脉流量恢复率,心排量恢复率和左室舒张末压恢复率以Mg^2 浓度8.0mmol/L和12.0mmol/L为优,0.4mmol/L组最差。2、心肌含水量以Mg^2 浓度8.0mmol/L和12.0mmol/L为最低。3、冠脉流出液乳酸盐含量0.4mmol/L组最差。2、心肌含水量以Mg^2 浓度8.0mmol/L和12.0mmol/L为最低。3、冠脉流出液乳桎卤含量0.4mmol/L组,8.0mmol/L和12.0mmol/L组高于其余2组。4、心肌乳酸脱氢酶漏出率以8.0mmol/L组最低,而肌酸激酶漏出率以8.0mmol/L和12.0mmol/L组为最低。5、心肌细胞内Na^2 含量以8.0mmol/L和12.0mmol/L组为最低,而心肌细胞内Ca^2 含量以8.0mmol/L组最低。6、心肌组织ATP含量以12.0mmol/L组为最高。7、心肌组织SOD活性以8.0mmol/L和12.0mmol/L组库最高,而MDA含量各组间总体差异无显著性。8、心肌超微结构;8.0mmol/L和12.0mmol/L组表现为基本正常未成熟心肌超微结构,而0.4mmol/L组超微结构有明显损伤表现。结论 对于未成熟心肌,当采用温血停搏液诱导停搏,冷血停搏液间断灌注,低温保护,温血停搏液终末控制性再灌注技术时,为避免含血停搏液Ca^2 浓度偏高对未成熟心肌的不利影响。应维持含血停搏液中Mg^2 浓度在8-12mmol/L。     

大鼠心脏低温保存及高钾停跳保护作用的ESR研究

用ESR研究大鼠离体心脏低温长时间缺血后再灌注时产生的自由基,并观察心肌超微结构的变化;对临床心脏直视手术中常用的高钾停跳液的保护作用机理进行了分析。实验结果表明超氧自由基信号强度随缺血温度的降低而明显减弱。高钾停跳液保护的大鼠离体心脏于低温(4℃)缺血后再灌15s,4h内超氧自由基信号强度变化不明显。缺血4h后再灌注,实验组心脏全部于15s内自动复跳,超微结构的变化轻微。以上改变与对照组比较有明显的差异。本实验为低温保存心脏及高钾停跳液的临床应用提供了实验依据。     

HTK液与冷血停搏液在心脏瓣膜手术中应用对比：倾向得分匹配分析

目的:比较HTK液与冷血停搏液在心脏瓣膜手术中应用效果,为临床心肌保护灌注策略提供依据。方法:采用单中心数据回顾性分析,选取2015年5月-2018年8月在体外循环下(CPB, Cardiopulmonary Bypass)应用灌注停跳液停跳的瓣膜手术患者529例,分为冷停液组(n=326)及HTK液组(n=203),采用倾向得分匹配方法将上述两组资料进行匹配,确定选取73对可匹配病例进行比较。采集的临床结果主要为CPB时间,阻断时间,ICU停留时间(intensive care unit length of stay,ICU LOS)以及血清钠术中术后浓度变化等参数。其次为,术后呼吸机辅助时间,IABP(Intra aortic ballon pump)的使用及新发透析,30天死亡率与术后主要并发症情况。结果:匹配后两组中冷停液组较HTK液组的主动脉平均阻断时间及CPB时间长,差异具有统计学意义(P0.05),HTK液组存在短暂性低血钠血症(P0.05),ICU LOS以及其余各临床结果无显著差异。结论:心脏瓣膜手术中应用HTK液与冷血停搏液临床早期结果一致,可根据手术操作流程及病人经济水平进行合理选择。     

del Nido心脏停搏液在主动脉夹层手术中的心肌保护效果

摘要 目的：探讨del Nido心脏停搏液在主动脉夹层手术中的心肌保护效果。方法：2015年2月到2020年6月选择在本院进行急诊手术的Stanford A型主动脉夹层的150例患者,入院后根据术中采用的心脏停搏液的不同分为两组 del Nido组与对照组各75例,所有患者都实施大血管外科手术,由同一组医师团队完成手术。Del Nido组给予del Nido心脏停博液灌注,对照组给予改良St. Thomas液灌注,记录心肌保护效果。结果：所有患者完成手术,两组的体外循环时间、停循环时间、阻断主动脉时间对比差异无统计学意义(P>0.05),del Nido组的灌注次数、总灌注时间、停博液晶体总量与对照组对比,差异有统计学意义(P<0.05)。Del Nido组的机械通气时间、ICU停留时间、术后住院时间短于对照组(P<0.05)。两组术后1 d的血清 cTnⅠ高于术前(P<0.05),del Nido组低于对照组(P<0.05)。两组术后7 d的院内死亡、心律失常、开胸止血、肾功能不全、肝功能不全等发生率对比差异无统计学意义(P>0.05)。结论：del Nido心脏停搏液在主动脉夹层手术中的能更好地发挥心肌保护效果,且不增加术后并发症的发生,减少灌注次数、总灌注时间,有利于促进患者康复。